Overactive Bladder TreatmentMarket Dynamics
High prevalence of overactivebladder is expected to propel the OveractiveBladder Treatment Market growth over the forecast period. Moreover,increasing awareness about the importance of diagnosis and treatment of thedisease is a key factor leading to increase in number of patients treated foroveractive bladder.
Furthermore, increasing number ofdrug development programs for overactive bladder is expected to fuel the overactivebladder treatment market growth, by adding new drug in the market. Currently,generic drugs such as cholinergic receptor inhibitors are available fortreatment of the condition. Therefore, development and approval of new drugentity with better drug profile is expected to boost the market growth.
For instance, in 2018, UrovantSciences—a biopharmaceutical company that focuses on developing novel therapyfor urologic conditions—entered in phase III clinical trial for its drug—Vibegron —an oral Beta-andrenergic agonist for indication of overactivebladder treatment.
Furthermore, Taris BiomedicalLLC—entered phase II clinical trials for its drug candidate TAR-302 for thetreatment of overactive bladder. TAR 302 is a trospium chloride-basedcontinuous local therapy, which is expected to efficiently aid in treatment ofoveractive bladder with few side effects.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2007
Key players operating in themarket are focused on development of combinational therapies. For instance, in2017, Astellas Pharma, Inc. received supplemental New Drug Application (sNDA)from FDA for conditional therapy of mirabegron and solifenacin succinate forthe treatment of urinary incontinence.
Overactive bladder is a commonmedical condition where there is sudden urge of urination. Overactive bladderis sometimes coupled with urine leakage, condition known as incontinence.Millions of people across the globe suffers from overactive bladder and it ismore common in old age people.
Urine leakage and frequenturination are the main symptoms of overactive bladder. The frequency ofurination in the patient is around eight times a day. Moreover, frequenturination during sleep hours is common in such patients. Overactive bladder iscommonly diagnosed by tests such as urine culture, bladder scan, cystoscopy orurodynamic testing.
Robust drug pipeline with drugsin phase II and phase III clinical trials, soon expected to be in the market,are expected to drive the overactive bladder treatment market growth. However,alternate therapies such as the neuromodulation therapy which includes sacralneuromodulation and percutaneous tibial nerve stimulation to deliver electricimpulse to nerve, are expected to hinder the overactive bladder treatmentmarket growth.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/overactive-bladder-treatment-market-2007
Overactive Bladder TreatmentMarket - Regional Analysis
The global overactive bladdertreatment market is segmented into six regions that include, North America,Latin America, Europe, Asia Pacific, Middle East, and Africa. North Americaoveractive bladder treatment market holds dominant position amongst otherregions, owing to high prevalence of overactive bladder in the region. Forinstance, according to the journal Current Bladder Dysfunction Reports, 2016review, millions of people suffer from overactive bladder in the U.S. andestimates continuous increase in cost of overactive bladder management.However, increasing awareness about the disease in Asia Pacific regions isexpected to boost the regional Asia Pacific overactive bladder treatment marketgrowth in the region, over the forecast period at a fast rate.
Overactive Bladder TreatmentMarket – Competitive Analysis
Key players operating in theoveractive bladder treatment market include, Janssen Pharmaceuticals Inc.,Accord Healthcare Inc., Mylan Pharmaceuticals Inc., Barr Laboratories Inc.(subsidiary of Teva Pharmaceuticals), Alembic Pharmaceuticals Ltd., PfizerInc., Astellas Pharma Inc., Endo International PLC, and Invagen PharmaceuticalsInc.
Key players operating in themarket are focusing on leveraging their expertise to develop novel treatmenttherapies for the disease, to enhance their market share. For instance, in2017, UroGen Pharma Ltd .a clinical-stage biopharmaceutical company incollaboration with Allergan Pharmaceuticals International Limited entered inphase II clinical trial for RTGel in combination with BOTOX, for overactivebladder treatment. RTGel is a hydrogel-based proprietary formulation of UroGenPharma Ltd.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2007
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
